文献速递临床试验与 GCP流行病学与生物统计真实世界研究与卫生经济

在非洲低出生体重儿稳定前实施袋鼠式母亲护理(OMWaNA):一项评估死亡率影响的随机对照试验方案

Operationalising kangaroo Mother care before stabilisation amongst low birth Weight Neonates in Africa (OMWaNA): protocol for a randomised controlled trial to examine mortality impact in Uganda.
PubMed 文献 · Trials · 2020-01-31

OMWaNA试验将在乌干达四中心开展开放标签、个体随机、优效性试验,纳入体重≥700-≤2000g、年龄≥1-<48h、KMC指征不确定的患儿2188例(每组1094例),比较稳定前启动KMC与标准护理对7天内死亡率的影响,并探索作用路径与成本效果。

要点

  • 稳定前启动KMC能否降低7天内死亡率尚缺乏证据,本试验将填补这一空白。
  • 纳入标准为体重≥700-≤2000g、年龄≥1-<48h且KMC指征不确定的住院新生儿。
  • 主要结局为7天内死亡率,次要结局包括28天死亡率、低体温、稳定时间等。

核心结论

  • OMWaNA试验旨在确定稳定前启动KMC相对于标准护理对7天内死亡率的影响,并评估增量成本与成本效果。

研究设计与样本

  • 在乌干达开展的四中心、开放标签、个体随机、优效性试验,两组平行对照。
  • 计划纳入2188例新生儿,干预组与对照组各1094例,按1:1随机分组并按体重和招募中心分层。
  • 纳入体重≥700-≤2000g、年龄≥1-<48h、KMC指征不确定的住院单胎、双胎或三胎新生儿。

关键数值与推荐

  • 主要结局为随机化后7天内死亡率。
  • 次要结局包括28天内死亡率、24小时低体温患病率、从随机化到稳定或死亡的时间、住院时长、从随机化到纯母乳喂养的时间、再入院频率、每日体重增长、母婴依恋及产后28天母亲 wellbeing。
  • 主要分析采用意向性治疗原则。

临床怎么用

  • 若证实有效,可为稳定前新生儿开展KMC提供证据,并可能适用于撒哈拉以南非洲和南亚等新生儿死亡高发地区的医院。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are 2.5 million neonatal deaths each year; the majority occur within 48 h of birth, before stabilisation. Evidence from 11 trials shows that kangaroo mother care (KMC) significantly reduces mortality in stabilised neonates; however, data on its effect among neonates before stabilisation are lacking. The OMWaNA trial aims to determine the effect of initiating KMC before stabilisation on mortality within seven days relative to standard care. Secondary objectives include exploring pathways for the intervention's effects and assessing incremental costs and cost-effectiveness between arms. METHODS: We will conduct a four-centre, open-label, individually randomised, superiority trial in Uganda with two parallel groups: an intervention arm allocated to receive KMC and a control arm receiving standard care. We will enrol 2188 neonates (1094 per arm) for whom the indication for KMC is 'uncertain', defined as receiving ≥ 1 therapy (e.g. oxygen). Admitted singleton, twin and triplet neonates (triplet if demise before admission of ≥ 1 baby) weighing ≥ 700-≤ 2000 g and aged ≥ 1-< 48 h are eligible. Treatment allocation is random in a 1:1 ratio between groups, stratified by weight and recruitment site. The primary outcome is mortality within seven days. Secondary outcomes include mortality within 28 days, hypothermia prevalence at 24 h, time from randomisation to stabilisation or death, admission duration, time from randomisation to exclusive breastmilk feeding, readmission frequency, daily weight gain, infant-caregiver attachment and women's wellbeing at 28 days. Primary analyses will be by intention-to-treat. Quantitative and qualitative data will be integrated in a process evaluation. Cost data will be collected and used in economic modelling. DISCUSSION: The OMWaNA trial aims to assess the effectiveness of KMC in reducing mortality among neonates before stabilisation, a vulnerable population for whom its benefits are uncertain. The trial will improve understanding of pathways underlying the intervention's effects and will be among the first to rigorously compare the incremental cost and cost-effectiveness of KMC relative to standard care. The findings are expected to have broad applicability to hospitals in sub-Saharan Africa and southern Asia, where three-quarters of global newborn deaths occur, as well as important policy and programme implications. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02811432. Registered on 23 June 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Medvedev MM, Tumukunde V, Mambule I, et al. Operationalising kangaroo Mother care before stabilisation amongst low birth Weight Neonates in Africa (OMWaNA): protocol for a randomised controlled trial to examine mortality impact in Uganda. Trials. 2020. PMID: 32005286. doi:10.1186/s13063-019-4044-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。